| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Metabolic enzymes and oxidative stress pathways. As a metabolite of acetaminophen, 3-hydroxy-acetaminophen is formed through metabolic pathways involving cytochrome P450 enzymes. It functions as an antioxidant by scavenging free radicals and reducing oxidative damage.
|
|---|---|
| ln Vitro |
3-Hydroxyacetaminophen exhibits free radical scavenging activity. It can reduce oxidative damage by exerting electron donation ability and antioxidant activity through its phenolic hydroxyl groups. These properties suggest it may protect cells from oxidative stress-induced damage, though specific IC50 values for antioxidant activity are not reported.
|
| ln Vivo |
No specific in vivo activity data is available for 3-hydroxy-acetaminophen beyond its role as a human metabolite of acetaminophen. It is formed in vivo following acetaminophen administration and is excreted in urine. Its antioxidant properties may contribute to the overall pharmacological and toxicological profile of acetaminophen.
|
| Enzyme Assay |
In vitro antioxidant assays for 3-hydroxyacetaminophen typically involve measuring its ability to scavenge free radicals using DPPH (2,2-diphenyl-1-picrylhydrazyl) or ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) assays. The compound's electron donation ability is assessed through its reaction with stable free radicals, with the decrease in absorbance measured spectrophotometrically.
|
| Cell Assay |
The in vitro antioxidant activity of 3-hydroxyacetaminophen can be evaluated in cell-free systems using DPPH or ABTS radical scavenging assays. In cellular models, its ability to reduce oxidative damage can be assessed in cultured cells exposed to oxidative stress inducers, with endpoints including reactive oxygen species (ROS) levels, lipid peroxidation, and cell viability.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for 3-hydroxy-acetaminophen. As a metabolite, it is typically studied in the context of acetaminophen metabolism and disposition. Animal studies involving acetaminophen administration would include measurement of 3-hydroxyacetaminophen levels in plasma and urine as part of pharmacokinetic or toxicokinetic analyses.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
3-Hydroxyacetaminophen is a known human metabolite of acetaminophen. 3-Hydroxyacetaminophen is a known human metabolite of acetaminophen. It is formed in the liver and excreted in urine. The compound has a molecular weight of 167.16 and formula C8H9NO3. Solubility: DMSO ~250 mg/mL (~1495.57 mM). Storage: powder at -20degC for 3 years; 4degC for 2 years. |
| Toxicity/Toxicokinetics |
No specific toxicological data is available for 3-hydroxy-acetaminophen. It is described as a non-toxic metabolite of acetaminophen. Unlike the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is associated with hepatotoxicity, 3-hydroxyacetaminophen is considered non-toxic.
|
| Additional Infomation |
3-Hydroxyacetaminophen is a non-toxic metabolite and antioxidant of acetaminophen with free radical scavenging activity. It is a known human metabolite of acetaminophen. The compound can reduce oxidative damage through electron donation and antioxidant activity via phenolic hydroxyl groups. It is not approved as a therapeutic agent and is intended for research use only.
|
| Molecular Formula |
C8H9NO3
|
|---|---|
| Molecular Weight |
167.16196
|
| Exact Mass |
167.058
|
| CAS # |
37519-14-5
|
| PubChem CID |
161950
|
| Appearance |
White to gray solid powder
|
| Density |
1.4g/cm3
|
| Boiling Point |
444.7ºC at 760 mmHg
|
| Melting Point |
170-172ºC
|
| Flash Point |
222.8ºC
|
| Index of Refraction |
1.664
|
| LogP |
1.129
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
172
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IPFBMHOMTSBTSU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H9NO3/c1-5(10)9-6-2-3-7(11)8(12)4-6/h2-4,11-12H,1H3,(H,9,10)
|
| Chemical Name |
N-(3,4-dihydroxyphenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1495.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.33 mg/mL (13.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.33 mg/mL (13.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.33 mg/mL (13.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL | |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL | |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
